CI has quietly recovered 4% this week to $286.62, yet the more striking shift is in how options traders are now positioned — moving from defensive hedging to the most call-heavy stance in nearly a year.
The options market has flipped decisively toward optimism. The put/call ratio dropped to 0.41, more than one standard deviation below its 20-day average of 0.51, and close to the 52-week low of 0.35. That's a sharp reversal from mid-June, when the PCR was running above 0.60 — near the annual high — as managed care names faced reimbursement uncertainty. The shift suggests investors are increasingly positioning for upside rather than protecting against further downside. The borrow market confirms there's no short-side pressure reinforcing that hedge: availability is extraordinarily loose at nearly 9,500%, meaning shares to borrow vastly outnumber those already borrowed. Short interest itself is modest at 2.6% of free float and fell roughly 7% on the week. Borrowing costs remain negligible at 0.53%. Nothing in the lending market reads as a crowded short.
The Street is divided but leans constructive, and the gap between bulls and skeptics is worth watching ahead of the July 30 Q2 print. The bullish camp — UBS with a $400 target, Morgan Stanley at $361, Bernstein at $371 — sees Cigna's Evernorth PBM franchise as a durable earnings engine, and the company's 2027 selling season retention tracking into the mid-90s supports that view. The skeptics are more recent: Deutsche Bank cut to Hold in late May, citing limited upside, and Barclays downgraded to Equal-Weight around the same time with a $304 target that barely clears the current price. The consensus mean target is $340, about 19% above current levels — a reasonable spread for a managed-care name trading at just 8.8x earnings and 7x EV/EBITDA, both of which have edged lower over the past 30 days. The PE multiple remains lean for the sector, and the dividend score ranks in the 99th percentile, suggesting the yield is well-supported relative to peers. Forward EPS momentum is modest — ranking in the 29th percentile for year-on-year growth — which explains why some analysts have moved to the sidelines even as valuation looks cheap.
The insider picture adds a note of caution. CEO David Cordani sold just over $19 million of stock on May 12 across multiple tranches at prices between $288 and $299 — close to where the stock trades today. Those sales came roughly two weeks after Q1 results, which themselves disappointed: the stock fell 3.9% on the day of that print, and gave up another 0.9% over the following week. The 90-day net insider position is a net sale of roughly $59.6 million in value. Execution has been the concern, not the franchise — which may explain why the CEO sold near current levels while institutional holders like BlackRock (8.5% stake, added 260,000 shares through June) and Sanders Capital (added 2.5 million shares as of March) have been building.
Peers have broadly outperformed CI on the week. EHC gained 9.7% and RDNT 14.4%, while MD added 8.7%. CVS and UNH each rose around 2%, more in line with Cigna's 4% weekly gain. The relative underperformance against the broader health services cohort over a longer horizon — CI was down roughly 12% year-to-date through mid-June per the recent peer note — has narrowed this week but not reversed.
With Q2 results due July 30, the key tension is whether the Evernorth margin story has stabilised enough to shift analyst sentiment back toward the upgrade camp, or whether another miss confirms the bear case that execution risk remains elevated at current multiples.
See the live data behind this article on ORTEX.
Open CI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
